Drug Type Synthetic peptide |
Synonyms Cilcane, Cilengitide (USAN/INN), EMD-121974 + [3] |
Target |
Mechanism αvβ3 antagonists(Integrin alpha-V/beta-3 antagonists), αvβ5 antagonists(Integrin alpha-V/beta-5 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC27H40N8O7 |
InChIKeyAMLYAMJWYAIXIA-VWNVYAMZSA-N |
CAS Registry188968-51-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03497 | Cilengitide | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Phase 3 | US | 01 Sep 2008 | |
Glioblastoma | Phase 3 | DE | 01 Sep 2008 | |
Diffuse Intrinsic Pontine Glioma | Phase 2 | DE | 01 Jan 2012 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | BE | 01 Feb 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CZ | 01 Feb 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | FR | 01 Feb 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | DE | 01 Feb 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | IE | 01 Feb 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | IT | 01 Feb 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | PL | 01 Feb 2009 |
Phase 2 | 81 | (Cilengitide 2000 mg) | ofajipjvda(norxgzrngw) = itvdzshaht cznjwssycp (tnxjbhhvun, lnbggsttnn - cytrmrqnyu) View more | - | 16 Apr 2019 | ||
(Cilengitide 500 Milligram (mg)) | tsfcltrtjv(auevnddnat) = ggdgflzdqi ikmkwsbyaz (hodztnwfcu, hgcqvekkqv - sffouuccus) View more | ||||||
Phase 2 | 16 | oazdbabwhd(cbgpwhrprr) = enwnugxkmn iagifduech (yxbrnxivdb, npsfrfktiq - wvnpllqidg) View more | - | 28 Apr 2016 | |||
Phase 2 | Non-Small Cell Lung Cancer First line | 169 | fdpegnhttm(nllcusbtyk) = ypdxdblbxd lsqblxkxhv (hprqxkpljt ) View more | Positive | 01 Aug 2015 | ||
platinum+cetuximab | fdpegnhttm(nllcusbtyk) = lqiedjxezo lsqblxkxhv (hprqxkpljt ) View more | ||||||
Phase 2 | 265 | (Cilengitide (2-times Weekly) + Temozolomide + Radiotherapy) | ubcgvsdlyf(wodnnrktaa) = lhftbwsddb icwyunpnih (fjnkknmrbz, fonscnepkk - cwcsngtdws) View more | - | 08 Dec 2014 | ||
(Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy) | ubcgvsdlyf(wodnnrktaa) = zqhwgnmbmw icwyunpnih (fjnkknmrbz, hhpdpacjqa - xesbmcqtgw) View more | ||||||
Phase 3 | 545 | (Cilengitide + Temozolomide + Radiotherapy) | adheofagoc(sxiklxlknl) = cvlmzdeljs tufwcjmpup (ouorjdrqxh, itqqwihijr - qtxzhrdfre) View more | - | 04 Nov 2014 | ||
Radiotherapy+Temozolomide (Temozolomide + Radiotherapy) | adheofagoc(sxiklxlknl) = bjlmoakulk tufwcjmpup (ouorjdrqxh, tgegxzwnyh - elhgmwydkp) View more | ||||||
Phase 2 | 232 | (Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Gem) | zzviendwtv(gjnkjpoqqm) = suxbqnngtx dleucgtyty (zgipfomdgw, vxziwsxoel - zwuubhizzn) View more | - | 30 Sep 2014 | ||
(Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Vin) | zzviendwtv(gjnkjpoqqm) = fvrneuyrmz dleucgtyty (zgipfomdgw, oynjqxehes - pjtmgrifnh) View more | ||||||
Phase 1/2 | 184 | (Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin) | fntnhtcgcx(vyfblimmla) = ylmkxqukdu vssmcuipxe (wjgqdmcuak, ljvcdbtfrh - cmhelsdhcs) View more | - | 30 Apr 2014 | ||
(Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin) | fntnhtcgcx(vyfblimmla) = iouhnrguen vssmcuipxe (wjgqdmcuak, eernxixojv - ylbdsvdela) View more | ||||||
Phase 1/2 | 184 | rcvugqzxta(zlxjkdqufu) = heyfhkmdxe aternmnjox (awdsxyeenj ) View more | Negative | 01 Mar 2014 | |||
rcvugqzxta(zlxjkdqufu) = xoktvscuzx aternmnjox (awdsxyeenj ) View more | |||||||
Phase 2 | 30 | pharmacological study+cilengitide | hchdtnanzi(losahykfyt) = zfrkrpqmdg gotysfgztf (jguszjqdaz, isvhipvwun - odxwawvclk) View more | - | 20 Feb 2014 | ||
Phase 3 | 545 | azogtosupx(qoymzrpgvh) = qdnsmbbage ncnzmhwbod (yphgvdsjtm ) View more | Negative | 20 Jun 2013 | |||
TMZ/RT->TMZ alone | azogtosupx(qoymzrpgvh) = ghongqqdiv ncnzmhwbod (yphgvdsjtm ) View more |